Events

Alerta De Seguridad para Cardioversor Defibrillator - Implantable model TACHOS DR or TACHOS ATx, brand BIOTRONIK - Cardioversor Implantable Defibrillator Model DEIKOS (DDDRD) or TUPOS LV / A + and Accessories: Key, Silicone glue, Mineral oil, BIOTRONIK brand.

Según Agência Nacional de Vigilância Sanitária (ANVISA), este evento ( alerta de seguridad ) involucró a un dispositivo médico en Brazil que fue producido por BIOTRONIK INDUSTRIA E COMERCIO LTDA.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • ID del evento
    722
  • Fecha
    2003-05-21
  • País del evento
    Brazil
  • Fuente del evento
    ANVISA
  • URL de la fuente del evento
    http://www.anvisa.gov.br/sistec/alerta/consultaralerta.asp
  • Notas / Alertas
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notas adicionales en la data
    TRADING NAME: CARDIOVERSOR DEFIBRILLADOR IMPLANTAVEL BIOTRONIK - REGISTER NUMBER: 10192030068 - COMMERCIAL NAME: CARDIOVERSOR DEFIBRILADOR IMPLANTAVEL BIOTRONIK - REGISTER NUMBER: 10192030070. To date, the doctors involved have already clinically followed 38 patients from the 45 units of Tachos DR and Delkos A + with the possibility of presenting the aforementioned phenomenon, adopting the measures recommended by the BIOTRONIK headquarters. The 7 missing patients will be followed up in the next few days. BIOTRONIK will forward updated recommendations for clinical follow-up whenever new information so warrants. BIOTRONIK points out that no other CDI manufactured by Biotronik has been affected by this phenomenon. The Department of Medical Engineering-BIOTRONIK sought to clarify the recommendations of our headquarters to the medical community. However, individual circumstances may determine another medical decision about patient care and the frequency of clinical follow-ups.
  • Causa
    A limited number of implantable cardioverter-defibrillators models tachos dr, tupos lv and deikos a + have recently exhibited an inexplicable high incidence of early battery failure. biotronik berlin conducted extensive research to determine the cause of this phenomenon. a specific batch of limnox batteries used in these models was identified that presented the formation of a passive layer covering the anode of the same. this material, formed on the anode, resulted in an increase in the internal impedance of the battery with consequent decrease of the voltage during load and that potentially limits its ability to generate the necessary amount of energy, preventing in the worst conditions the delivery of the shock.
  • Acción
    Biotronik Brasil followed daily the investigations of our matrix and anticipated the measures with the medical community and patients who received the implants of the units involved in certain specific batches.

Device

Cardioversor Defibrillator - Implantable model TACHOS DR or TACHOS ATx, brand BIOTRONIK - Cardiov...

Manufacturer

BIOTRONIK INDUSTRIA E COMERCIO LTDA
  • Comentario del fabricante
    Biotronik told ICIJ that, when it identifies the need to issue a recall, the company immediately informs physicians of all potentially affected patients. It also noted that product recalls for all manufactures are publically available on the relevant national authorities’ websites. “As soon as an event is deemed serious either by a hospital or a manufacturer, it is reported inter alia to the regulatory authority in the country in which the incidence has occurred, as well as to the FDA for US-approved devices, even if the event has occurred outside of the US,” the company said.
  • Source
    ANVSANVISA